 AUSTIN, TX and DURHAM, NC, Feb. 09, 2022 GLOBE NEWSWIRE -- Shattuck Labs, Inc. Shattuck NASDAQ: STTK , a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in the 11th Annual SVB Leerink Global Healthcare Conference being held February 14-18, 2022. 